CD19 and neoplasm: Additionally, several factors influence the effectiveness of CAR T-cell therapy, including a pro-inflammatory state, the tumor microenvironment, PPM1D mutations, single nucleotide polymorphisms in the cluster of differentiation 19 (CD19) antigens, and circulating monocytes.